Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2010 1
2011 5
2012 2
2015 1
2017 1
2019 2
2020 2
2021 2
2023 3

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Population Pharmacokinetic Modeling and Determination of Individual Exposure to Avalglucosidase Alfa in Adolescent and Adult Patients With Late-Onset Pompe Disease: Analysis of Pooled Data From Phase I to III Clinical Trials.
Tuffal G, Tiraboschi G, Hurbin F, Boittet P, Palmer R, Martinez JM, Fabre D. Tuffal G, et al. Among authors: hurbin f. Ther Drug Monit. 2023 Oct 1;45(5):644-652. doi: 10.1097/FTD.0000000000001086. Epub 2023 Aug 1. Ther Drug Monit. 2023. PMID: 37556417 Free PMC article.
Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease.
Tiraboschi G, Marchionni D, Tuffal G, Fabre D, Martinez JM, Haack KA, Miossec P, Kittner B, Daba N, Hurbin F. Tiraboschi G, et al. Among authors: hurbin f. J Pharmacokinet Pharmacodyn. 2023 Aug 3. doi: 10.1007/s10928-023-09874-8. Online ahead of print. J Pharmacokinet Pharmacodyn. 2023. PMID: 37535240
Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial.
Bergougnan L, Andersen G, Plum-Mörschel L, Evaristi MF, Poirier B, Tardat A, Ermer M, Herbrand T, Arrubla J, Coester HV, Sansone R, Heiss C, Vitse O, Hurbin F, Boiron R, Benain X, Radzik D, Janiak P, Muslin AJ, Hovsepian L, Kirkesseli S, Deutsch P, Parkar AA. Bergougnan L, et al. Among authors: hurbin f. Br J Clin Pharmacol. 2021 May;87(5):2303-2320. doi: 10.1111/bcp.14632. Epub 2020 Nov 26. Br J Clin Pharmacol. 2021. PMID: 33125753 Free PMC article. Clinical Trial.
First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection.
Bergougnan L, Armani S, Golor G, Tardat A, Vitse O, Hurbin F, Scemama M, Poitiers F, Radzik D, Gaudin C, Hovsepian L, Muslin AJ, Kirkesseli S, Deutsch P, Parkar AA. Bergougnan L, et al. Among authors: hurbin f. Br J Clin Pharmacol. 2021 Feb;87(2):598-611. doi: 10.1111/bcp.14422. Epub 2020 Jul 8. Br J Clin Pharmacol. 2021. PMID: 32520410 Free PMC article. Clinical Trial.
Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model-Support for a Biologics License Application Submission: Part I.
Martinez JM, Brunet A, Hurbin F, DiCioccio AT, Rauch C, Fabre D. Martinez JM, et al. Among authors: hurbin f. Clin Pharmacokinet. 2019 Jan;58(1):101-113. doi: 10.1007/s40262-018-0669-y. Clin Pharmacokinet. 2019. PMID: 29725996 Free PMC article. Clinical Trial.
Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II.
Nicolas X, Djebli N, Rauch C, Brunet A, Hurbin F, Martinez JM, Fabre D. Nicolas X, et al. Among authors: hurbin f. Clin Pharmacokinet. 2019 Jan;58(1):115-130. doi: 10.1007/s40262-018-0670-5. Clin Pharmacokinet. 2019. PMID: 29725997 Free PMC article. Clinical Trial.
16 results